Affymetrix (Santa Clara, California) Signs First Translational Medicine Agreement In China; Zhejiang University To Use GeneChip(R) Microarray Technology To Better Detect, Classify, Manage And Treat Cancer And Infectious Diseases

SANTA CLARA, Calif.--(BUSINESS WIRE)--Sept. 18, 2006--Affymetrix Inc. (Nasdaq:AFFX) and Zhejiang California Nanosystem Institute (ZCNI) at Zhejiang University announced today that they have entered into a collaboration to develop clinical applications using GeneChip(R) technology. This is Affymetrix' first translational medicine collaboration in China. Under terms of the agreement, ZCNI researchers will use Affymetrix GeneChip microarray technology for translational medicine research projects, beginning with cancer, newborn genetic diseases and infectious diseases.